|Bid||34.59 x N/A|
|Ask||34.60 x N/A|
|Day's Range||34.51 - 35.43|
|52 Week Range||30.53 - 75.49|
|Beta (5Y Monthly)||1.77|
|PE Ratio (TTM)||115.30|
|Earnings Date||Apr 29, 2022 - May 02, 2022|
|Forward Dividend & Yield||0.30 (0.88%)|
|Ex-Dividend Date||Jun 20, 2022|
|1y Target Est||N/A|
COLORADO SPRINGS, CO / ACCESSWIRE / May 4, 2022 / Fortitude Gold Corporation (OTCQB:FTCO) (the "Company") reported results for the first quarter ended March 31, 2022, including $15.3 million cash balance at quarter end.
COLORADO SPRINGS, CO / ACCESSWIRE / April 18, 2022 / Fortitude Gold Corp. (OTCQB:FTCO) (the "Company") reports preliminary production results for the first quarter ended March 31, 2022 of 9,875 gold ounces.
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, single, ascending dose clinical study in the U.S. for the company's investigational drug, GZR18. GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes. Currently, type 2 diabetes mellitus accounts for approx